COMPARE · Data as of August 28, 2026

NLY vs STWD

Verdict: Side-by-side breakdown using the Bull Rankings model. NLY scored 70.0, STWD scored 61.0 — NLY leads.
Compare another set
NLY
Annaly Capital Management, Inc.
REIT - Mortgage · Financial strength
72.6Fin
$23.04 · $17.4B
fundamentals as of
Strength gap
7.5
NLY leads
STWD
Starwood Property Trust, Inc.
REIT - Mortgage · Financial strength
65.1Fin
$15.81 · $6.0B
fundamentals as of
  • Fastest growthNLY+87.3%
  • Strongest balance sheetSTWD3.31
THE BULL RANKINGS SCORECARD72.6/ 100 · FIN STRENGTHPEER MEDIANREIT72.6
THE BULL RANKINGS SCORECARD65.1/ 100 · FIN STRENGTHPEER MEDIANREIT65.1
YieldNLY13.0%STWD12.0%
RevNLY+87.3%STWD-13.8%
D/ENLY7.38STWD3.31
NLY
STWD
13.0%C+
Yield
12.0%C+
+87.3%A
Rev
-13.8%D
7.38D
D/E
3.31C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
NLYAnnaly Capital Management, Inc.
REIT - Mortgage · $23.04 · beta 1.24
Why now
REIT - Mortgage · market cap $17.4b. 6% off the 52-week high of $24.52. Revenue growing +87% — in hypergrowth territory. 11 sell-side analysts publish a mean 1-yr target of $24.23 (implying +5% upside).
Moat
Net margin 91% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
D/E 7.38 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
STWDStarwood Property Trust, Inc.
REIT - Mortgage · $15.81 · beta 1.04
Why now
REIT - Mortgage · market cap $6.0b. Down 24% from 52-week high of $20.84 — deep drawdown territory. Revenue -14% — in contraction; any catalyst that reverses this triggers re-rating. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $19.88 (implying +26% upside).
Moat
Net margin 38% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma.
Risk
D/E 3.31 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Revenue contracting -14% — the operational turn is not yet visible in the top line. Dividend payout 325% of earnings on a 12.0% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.